Users of the Ortho Evra birth control patch (Ortho McNeil Pharmaceuticals) are exposed to higher overall levels of estrogen than users of birth control pills and thus may be at higher risk for blood clots and other serious side effects, according to the FDA.
Users of the Ortho Evra birth control patch (Ortho McNeil Pharmaceuticals) are exposed to higher overall levels of estrogen than users of birth control pills and thus may be at higher risk for blood clots and other serious side effects, according to the FDA.
Recently updated labeling for the product now states that women who use Ortho Evra are exposed to about 60% more total estrogen in their blood than women taking a typical birth control pill containing 35 μg of estrogen. This is because hormones from the patch enter the bloodstream directly, while pills are swallowed and digested first, losing about half their estrogen dose in the process. While the peak blood level of estrogen is about 25% lower with the patch than with the Pill, estrogen levels with the patch remain relatively constant for about 1 week until the patch is removed, whereas peak blood levels with the Pill, which generally occur within 1 or 2 hours of taking it, rapidly decline over a 12-hour period to levels that are lower than with the patch. This means the body is not exposed to high levels of estrogen 24 hours per day.
For more information, call the Center for Drug's Division of Drug Information at 888-INFO-FDA (888-463-6332) or visit http://www.fda.gov/cder/drug/infopage/orthoevra/default.htm.
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
Trimethoprim–sulfamethoxazole not found to increase infant birth weight in HIV cases
July 9th 2025A recent randomized trial found no significant improvement in birth weight or key birth outcomes from antenatal trimethoprim–sulfamethoxazole prophylaxis in human immunodeficiency virus-positive pregnant women.
Read More